Growth retardation and osteomalacia as a result of ifosfamide nephrotoxicity in a 3-year-old boy whose genotype reveals the genes encoding glutathione S-transferases GSTM1 and GSTT1

Cytobios

Volumn 2001, Issue 413, 2001, Pages 193-200

  Zielińska, Elzbieta ^a   Bodalski, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Alkylating agents; Children; Genotype; Glutathione S transferase classes GSTM1; Growth retardation; GSTT1; Nephrotoxicity

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; IFOSFAMIDE;

ARTICLE; BACK; CASE REPORT; DRUG EFFECT; ELECTROLYTE BALANCE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; GROWTH DISORDER; HUMAN; KIDNEY; KIDNEY DISEASE; MALE; OSTEOMALACIA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; RADIOGRAPHY; TERATOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; GROWTH DISORDERS; HUMANS; IFOSFAMIDE; KIDNEY; KIDNEY DISEASES; MALE; OSTEOMALACIA; SACROCOCCYGEAL REGION; TERATOMA; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 0035224629     PISSN: 00114529     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. BODDY A. V., English M., Pearson A. D. J., Idle J. R. and Skinner R. 1996. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur. J. Cancer 32A 1179-84.
2. BRÜGGEMANN S. K., Kisro J. and Wagner T. 1997. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res. 57 2676-80.
3. CANAL P. 1998. Platinum compounds: pharmacokinetics and pharmacodynamics. In Clinican's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. pp 345-73. Edited by L. B. Grochow and M. M. Ames. Williams & Wilkins, Baltimore, Philadelphia.
4. CHEN H., Sandler D. P., Taylor J. A., Shore D. L., Liu E., Bloomfield C. D. and Bell D. A. 1996. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 gene defect. Lancet 347 295-7.
5. CIACCIO P. J. and Tew K. D. 1993. Glutathione S-transferases. In Drug Resistance in Oncology. pp 351-74. Edited by B. A. Teicher. Marcel Dekker, New York.
6. DALY A. K. 1995 Molecular basis of polymorphic drug metabolism. J. molec. Med. 73 539-53.
7. 6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. Eur. J. Cancer 34 1749-55.
8. FOXALL P. J. D., Lenz E. M., Lindon J. C., Neild G. H., Wilson I. D. and Nicholson J. K. 1996. Nuclear magnetic resonance and high performance liquid chromatography -nuclear magnetic resonance studies on the toxicity and metabolism of ifosfamide. Ther. Drug Monit. 18 498-505.
9. FOXALL P. J. D., Singer J. M., Hartley J. M., Neild G. H., Lapsley M., Nicholson J. K. and Souhami R. L. 1997. Urinary proton magnetic resonance studies of early ifosfamide induced nephrotoxicity and encephalopathy. Clin. Cancer Res. 8 1507-18.
10. GALLOE A. M., Graudal N., Christensen H. R. and Kampmann J. P. 1995. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur. J. clin. Pharmacol. 48 39-43.
11. HENEY D., Lewis I. and Bailey C. 1989 Acute ifosfamide-induced tubular toxicity. Lancet 2 103-4.
12. KAIJSER G. P. and Beijnen J. H. 1998 Oxazaphosphorines: cyclophosphamide and ifosfamide. In Clinican's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. pp 229-58. Edited by L. B. Grochow and M. M. Ames. Williams & Wilkins, Baltimore, Philadelphia.
13. MULDERS T. M. T., Keizer H. J., Ouwerkerk J., van der Velde E. A., Breimer D. D. and Mulder G. 1995. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Clin. Cancer Res. 1 1525-36.
14. NIEDŹWIECKA Z. and Palczewska J. 1997. Physical development standards for infants in the first 3 years of life. Medycyna Wieku Rozwojowegon. 1 (Suppl) 3-71.
15. ROSSI R., Gödde A., Kleinebrand A., Riepenhausen M., Boos J., Ritter J. and Jürgens H. 1994. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide induced nephrotoxicity of 120 patients. J. clin. Oncol. 12 159-65.
16. RUSSO D., Marie J. P., Zhou D. C., Faussat A. M., Delmer A., Malsonneuve L., Ngoc L. H., Baccarani M. and Zittoun R. 1994. Coexpression of anionic glutathione-S-transferase (GSTπ) and multidrug resistance (mdrl) genes in acute myeloid and lymphoid leukemias. Leukemia 8 881-4.
17. SKINNER R., Sharkey I. M., Pearson A. D. and Craft A. W. 1993. Ifosfamide MESNA and nephrotoxicity in children. J. clin. Oncol. 11 173-90.
18. WORMER R. B. 1996 Ifosfamide and paediatrics: should this marriage be saved? Eur. J. Cancer 32A 1100-1.